Scynexis (NASDAQ:SCYX) price target upped to $8.00, released a report earlier today by WBB Securities
- Updated: October 6, 2016
Having a price of $4.82, Scynexis (NASDAQ:SCYX) traded 0.42% higher on the day. With the last close up 50.95% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. SCYX has recorded a 50-day average of $3.36 and a two hundred day average of $3.19. Trading volume was up over the average, with 3,907,322 shares of SCYX changing hands over the typical 788,408
Stating a potential upside of 0.66%, WBB Securities increased the stock price target of Scynexis (NASDAQ:SCYX) to $8.00
On 10/03/2016, Brean Capital released a statement on Scynexis (NASDAQ:SCYX) upped the target price from $0.00 to $16.00 that suggested an upside of 3.13%.
With a total market value of $0, Scynexis has with a one year low of $1.74 and a one year high of $7.69 .
A total of 5 analysts have released a report on the company. 1 broker rating the stock a strong buy, 4 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $14.40.
General Company Details For Scynexis (NASDAQ:SCYX)
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.